Search clinical trials for: formoterol Turbuhaler

Total 485 results

AstraZeneca

Completed

Evaluation of Efficacy and Safety of Formoterol in Patients With COPD Compared With Placebo in Patients in Japan, EU (OCEAN)

Chronic Obstructive Pulmonary Disease

Bulgaria, Russian Federation, Romania, Ukraine, Japan
Meir Medical Center

Unknown

Study of Preventive Treatment With Symbicort or Budicort Turbohaler in Childhood Asthma Return to School Epidemic

Asthma Exacerbation

Israel
AstraZeneca

Completed

Efficacy and Safety Study of Symbicort® Turbuhaler® Versus Oxis® Turbuhaler® in Chronic Obstructive Pulmonary Disease (COPD) Patients (SUMIRE)

Chronic Obstructive Pulmonary Disease

Korea, Republic of, Poland, Russian Federation, Vietnam, Philippines, Ukraine, Japan, Taiwan, India
Istituto per la Ricerca e l'Innovazione Biomedica

Completed

The Use of an Innovative Device for Therapeutic Adherence in Pediatric Asthma

Asthma

Italy
AstraZeneca

Completed

Evaluation of Efficacy on Exercise Tolerance of Symbicort (Budesonide/Formoterol) Compared to Placebo and Oxis in Patients With Severe COPD (CODEX)

Chronic Obstructive Pulmonary Disease

Germany, Switzerland
AstraZeneca

Terminated

A Multiple Ascending Dose Study With AZD9164 Given for 13 Days in Healthy Male and Female Subjects and in Patients With Chronic Obstructive Pulmonary Disease

Healthy | COPD

Sweden
AstraZeneca

Completed

Comparing the Efficacy of Symbicort® pMDI and Formoterol Turbuhaler in Reducing Exacerbations in Patients With Cronic Obstructive Pulmonary Disease (RISE)

COPD Patients

United States, Spain, Bulgaria, Mexico, Poland, South Africa, Germany, Argentina, Chile, Czechia, Puerto Rico
AstraZeneca

Completed

Evaluation of an Oxygen Enhanced Magnetic Resonance Imaging Method on Patients With Chronic Obstructive Pulmonary Disease During 8 Weeks Treatment With Either Symbicort Turbuhaler or Oxis Turbuhaler

COPD Method Evaluation | Chronic Obstructive Pulmonary Disease Method Evaluation

United Kingdom, Sweden
AstraZeneca

Completed

Symbicort Maintenance and Reliever Therapy - Experience in Real Life Setting in Malaysia (SMARTER)

Asthma

Malaysia
Orion Corporation, Orion Pharma

Completed

To Confirm Equivalent Bronchodilator Efficacy of the Test Product Compared to the Reference Product (BUFODIL)

Asthma

Bulgaria
AstraZeneca

Completed

Study Comparing Dual Combination of Product (Budesonide and Formoterol) Given Via Two Different Inhalers. To See Which One Results in the Best Effect on Breathing.

Chronic Obstructive Pulmonary Disease (COPD)

Germany
Orion Corporation, Orion Pharma

Completed

Pharmacokinetic Study to Compare Absorption of Budesonide/Formoterol Easyhaler and Symbicort Turbuhaler

Asthma

Finland
Research in Real-Life Ltd
Teva Branded Pharmaceutical Products R&D, Inc.; University of Sydney; The University... and other collaborators

Completed

Comparing Maintenance of Device Mastery With Turbohaler© vs. Spiromax© in Healthcare Professionals naïve to Both Devices (HCP-ELIOT)

Asthma
Orion Corporation, Orion Pharma

Completed

Pharmacokinetic Study Comparing Budesonide/Formoterol Easyhaler and Symbicort Turbuhaler Forte (ADECO)

Asthma

Germany
AstraZeneca

Completed

Effect of Budesonide / Formoterol Combination in Repeated AMP Provocations

Asthma

Netherlands
Mundipharma Research Limited

Completed

Assessment of the Efficacy and Safety of FlutiForm® pMDI 125/5 µg (2 Puffs Bid) Versus Symbicort® Turbohaler® 200/6 µg (2 Puffs Bid) in Adolescent and Adult Subjects With Moderate to Severe Persistent, Reversible Asthma

Asthma

Poland, Bulgaria, Romania, India, Hungary
AstraZeneca

Completed

A Comparison of the Control of Asthma Provided by Symbicort® Turbuhaler® Versus Symbicort® Turbuhaler® Plus Pulmicort® Turbuhaler® Plus Terbutaline Turbuhaler®

Asthma

Sweden, France, United Kingdom, Germany, Denmark, Spain
AstraZeneca

Completed

Comparing Symbicort® As-Needed or Bricanyl As-Needed or Pulmicort® Once Daily + Bricanyl As-Needed in Asthma Patients (MIA)

Exercise Induced Asthma

Sweden, Norway
AstraZeneca

Completed

A Safety and Efficacy Study of Symbicort Turbuhaler Compared With Standard Chronic Obstructive Pulmonary Disease (COPD) Treatment in Japan

Chronic Obstructive Pulmonary Disease

Japan
University Hospital, Antwerp
AstraZeneca

Completed

Assess Particle Deposition and Acute Effects of Symbicort® Forte Turbohaler®) in COPD Patients.

Chronic Obstructive Pulmonary Disease

Belgium
AstraZeneca

Completed

Symbicort Rapihaler Therapeutic Equivalence Study (ESTHER)

Bronchial Asthma

Bulgaria, Czech Republic, Poland, Hungary
Orion Corporation, Orion Pharma

Completed

Comparison of Absorption of Budesonide and Formoterol From Budesonide/Formoterol Easyhaler and Symbicort Turbuhaler

Asthma

Finland
Chiesi Farmaceutici S.p.A.

Completed

Foster® pMDI (CHF 1535) Versus Symbicort® Turbohaler in COPD Patient (FORSYYN)

Chronic Obstructive Pulmonary Disease

China
Fundación Pública Andaluza Progreso y Salud

Completed

Errors in the Use of Turbuhaler and Spiromax Devices Patients With Asthma

Asthma

Spain
AstraZeneca

Completed

A Comparison of SYMBICORT® pMDI With Formoterol Turbuhaler® in Subjects With COPD

Chronic Obstructive Pulmonary Disease

United States, Peru, South Africa, Argentina, Mexico, Brazil, Chile, Colombia, Venezuela
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Study to Evaluate the Mastery of Inhaler Technique for Budesonide Formoterol (BF) SPIROMAX® as Compared to SYMBICORT® TURBOHALER® as Treatment for Adult Participants With Asthma (ELIOT)

Asthma

United Kingdom
Sunovion

Completed

Safety and Efficacy of Arformoterol Tartrate Inhalation Solution in Subjects With Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease | Emphysema | Bronchitis

United States
Air Force Military Medical University, China

Unknown

Study of Bosentan in the Treatment of Stable Severe Chronic Obstructive Pulmonary Disease Patients (BTCOPD)

Chronic Obstructive Pulmonary Disease (COPD)

China
GlaxoSmithKline

Completed

To Study Device Attributes by Investigating Errors Made in Use, Ease of Use and Preference Among Different Inhalers in Subjects With Asthma

Asthma

United Kingdom, Netherlands
Pearl Therapeutics, Inc.

Completed

Pharmacokinetics and Safety Study of PT010 in Healthy Subjects

COPD

United States
AstraZeneca

Completed

Efficacy and Safety Study of Symbicort Turbuhaler in Chinese Patients With COPD

Chronic Obstructive Pulmonary Disease

China
Zambon SpA
FLUIDDA nv

Completed

Study to Compare the Effects of Z7200 And Symbicort® Turbohaler on Respiratory Imaging Parameters in Asthmatic Patients

Asthma | Asthma Chronic | Asthmatic | Asthma Bronchial

Belgium
AstraZeneca

Completed

Study to Evaluate the Safety and Efficacy of Formoterol in a Daily Dose of 18 µg (9 µg Twice Daily) in Japanese Chronic Obstructive Pulmonary Disease (COPD) Patients

Chronic Obstructive Pulmonary Disease

Japan
Zambon SpA

Completed

A Clinical Study to Evaluate Z7200 (Budesonide/Formoterol) Pharmacokinetics Profile in Healthy Volunteers

Asthma

United Kingdom
AstraZeneca

Completed

Relative Bronchodilating Effects of Formoterol When Administered Via Symbicort Pressurized Metered-dose Inhaler (pMDI) or Oxis Turbuhaler

Stable Asthma
AstraZeneca

Completed

A Comparison of Symbicort® pMDI 2 x 160/4.5 μg Bid and 2 x 80/4.5 μg Bid With Formoterol Turbuhaler® 2 x 4.5 μg Bid and Placebo in Patients With COPD

Chronic Obstructive Pulmonary Disease

United States, Bulgaria, Germany, Hungary, Romania, Denmark, Greece, Mexico, Iceland
Orion Corporation, Orion Pharma

Completed

Pharmacokinetic Pilot Study on Budesonide/Formoterol Device-metered Dry Powder Inhaler

Healthy

Finland
Zambon SpA

Completed

Clinical Study to Evaluate Z7200 Pharmacokinetics Profile

Asthma

United Kingdom
Hat Yai Medical Education Center

Completed

As-needed Budesonide/Formoterol Turbuhaler in Stepping Down Period

Asthma

Thailand
AstraZeneca

Completed

A Comparison of Symbicort® pMDI 2 x 160/4.5 μg Bid and Symbicort® pMDI 2 x 80/4.5 μg Bid With Formoterol Turbuhaler®, Budesonide pMDI, the Combination of Formoterol Turbuhaler® and Budesonide pMDI, and Placebo in COPD Patients

Chronic Obstructive Pulmonary Disease

United States, Czech Republic, Poland, South Africa, Netherlands
GlaxoSmithKline

Completed

Study of Inhaler Device Attributes Investigating Critical and Overall Errors, Ease of Use, and Preference Between a Number of Inhaler Devices

Pulmonary Disease, Chronic Obstructive

United Kingdom, Netherlands
AstraZeneca

Terminated

Symbicort Single Inhaler Therapy vs Conventional Best Practice for the Treatment of Persistent Asthma in Adults

Asthma, Bronchial

Spain
GlaxoSmithKline

Completed

Influence Of Different Airflow Resistances On Drug Effect Of 50μg Salmeterol And 6 μg Formoterol

Asthma

Germany
Chiesi Farmaceutici S.p.A.

Terminated

A Study in Patients With Chronic Obstructive Pulmonary Disease (FAIR) (FAIR)

Chronic Obstructive Pulmonary Disease

Netherlands
Bispebjerg Hospital
Hormone Laboratory, Aker University Hospital, Oslo, Norway

Unknown

Concentrations of Formoterol in Blood and Urine

Asthma

Denmark
Actavis Inc.
Teva Pharmaceuticals USA

Completed

Randomized, Placebo-Controlled, Multidose, Study Comparing Generic Budesonide/Formoterol Fumarate Dihydrate to Symbicort® in Asthmatic Participants

Asthma

United States
AstraZeneca

Completed

Study to Investigate the Efficacy of Symbicort® SMART. (SAKURA)

Asthma

Korea, Republic of, Peru, Philippines, China, Malaysia, Hungary, Japan, Argentina, Thailand, India, Brazil, Costa Rica
Orion Corporation, Orion Pharma

Completed

Comparison of Budesonide and Formoterol Absorption From Budesonide/Formoterol Easyhaler and Symbicort Turbuhaler

Asthma

Finland
Sunovion

Completed

To Evaluate the Long-term Safety of (R,R)-Formoterol in Subjects With COPD

Chronic Obstructive Pulmonary Disease | Emphysema | Chronic Bronchitis

United States
Consorzio Futuro in Ricerca

Completed

Comparative Study on Usability of Inhaler Devices in Adults With Asthma or COPD (PMC-101-APT)

Asthma | COPD

Italy

3

Subscribe